Population study of dihydropyrimidine dehydrogenase in cancer patients.

M C Etienne, J.-L. Lagrange, O. Dassonville, +6

Journal of Clinical Oncology

Improved survival using specialized multidisciplinary board in sarcoma patients

Jean‐Yves Blay, Pauline Soibinet, Nicolas Penel, +27

Annals of Oncology

Surgical OncologySpecialized Multidisciplinary BoardMedicineCancer ManagementPrognosis +3

Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial

Richard Delarue, Hervé Tilly, Nicolas Mounier, +17

The Lancet Oncology

Hematological MalignancyDose-dense Rituximab-chopStandard Rituximab-chopLymphoid NeoplasiaElderly Patients +4

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.

Bob Löwenberg, Stefan Suciu, E Archimbaud, +14

Journal of Clinical Oncology

Low-energy He/Ne laser in the prevention of radiation-induced mucositis

R.J. Bensadoun, J C Franquin, Gaston Ciais, +15

Supportive Care in Cancer

Low-energy He/ne LaserRadiation OncologyNon-ionizing RadiationRadiation Application

CLINICAL AND PHARMACOKINETIC EVIDENCE OF A LIFE-THREATENING INTERACTION BETWEEN METHOTREXATE AND KETOPROFEN

A. Thyss, Johanna Kubar, G. Milano, +2

The Lancet

Pharmacological StudyPharmacologyClinical PharmacologyPharmacotherapyMedicine +1

Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group

M. Schlemmer, Peter Reichardt, Jaap Verweij, +7

European Journal of Cancer

Surgical OncologyTumoral PathologyBone Sarcoma GroupMedicinePathology +6

Upfront VIP‐reinforced‐ABVD (VIP‐rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS‐LTP95

Audrey Simon, Michel Péoc’h, Philippe Casassus, +17

British Journal of Haematology

Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group

Antoîne Italiano, Nicolas Penel, Y Robin, +12

Annals of Oncology

Surgical OncologyMedicineNeo/adjuvant ChemotherapyOncologyRadiation Oncology +1

Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG)

Delphine Garbay, Axel Le Cesne, Nicolas Penel, +12

Annals of Oncology

Malignant DiseaseMedicinePathologyFrench Sarcoma GroupCancer Treatment +5